Financing a Cure for Diabetes in a Multipayer Environment.

Area of Science:

• Health economics
• Medical financing innovation
• Biopharmaceutical market analysis

Background:

• Financing medical breakthroughs faces fiscal challenges.
• Current systems may not adequately incentivize investment in cures.
• Need for novel financial models in healthcare.

Purpose of the Study:

• Develop precise conditions for a HealthCoin financing mechanism.
• Incentivize private payers to invest in breakthrough therapies/cures.
• Establish HealthCoin feasibility between private payers and Medicare in the US.

Main Methods:

• Valuation modeling of a HealthCoin for a Type 2 diabetes cure.
• Comparative analysis of financing scenarios (with and without HealthCoin).
• Stakeholder analysis (private payer, Medicare, manufacturer).

Main Results:

• Without HealthCoin, private payers underinvest in cures, leading to limited patient access and Medicare losses.
• HealthCoin enables private payer investment in cures during non-elderly ages.
• HealthCoin achieves Pareto improvements for private payers, Medicare, and manufacturers.

Conclusions:

• HealthCoin presents a feasible financing model for breakthrough therapies.
• Applicability extends to gene therapies for blindness and hemophilia B.
• Legislation and demonstration projects are key to instituting HealthCoin payments.